MedTech startup Magnendo announced on the 11th that it has secured investment from BASS Ventures and Kakao Ventures, with both firms participating in the pre-seed and pre-seed bridge stages.  

Headquartered in Boston, USA, Magnendo is developing robotics technology to make brain neurotherapy procedures faster and safer. Its Magnetic Steering & Navigation technology enables precise and safe access to blood vessels that are difficult to reach using conventional methods. By offering a more efficient and secure approach, the company aims to reduce complications in brain neurotherapy while improving procedural efficiency for medical professionals.  

Treatments for conditions such as strokes and cerebral aneurysms require highly precise interventions in complex vascular structures within a critical timeframe, making them particularly challenging. Limited vascular access can delay treatment, leading to worsened clinical outcomes and a higher risk of complications, including vascular damage. Magnendo’s magnetic field-based technology is designed to overcome these challenges, ultimately expanding treatment opportunities for more patients.  

With this investment, Magnendo plans to accelerate research on its robotic platform for brain neurotherapy and strengthen collaborations with medical institutions. The company also aims to expand its technology into various applications, such as remote treatment, and establish a new standard in brain neurotherapy.  

Jung-ho Shin, Senior Analyst at Kakao Ventures, stated, “CEO Yoon-ho Kim, who built a strong research foundation at MIT, has spent the past few years validating Magnendo’s robotics platform in collaboration with multinational corporate partners. One of the company’s biggest strengths is its impressive team, which includes key leaders with business development and regulatory expertise from global medical robotics firms.”  

Dong-eon Choi, Principal at BASS Ventures, added, “Magnendo’s technology is an innovative solution that overcomes the limitations of conventional neurovascular procedures. As remote treatment and automated surgery gain global attention, Magnendo’s robotics technology is well-positioned to set a new standard in neurotherapy.”  

Yoon-ho Kim, CEO of Magnendo, remarked, “We are committed to driving innovation in brain neurotherapy to ensure better outcomes for both patients and medical professionals.”